146 related articles for article (PubMed ID: 21110957)
1. Ligand stimulation of ErbB4 and a constitutively-active ErbB4 mutant result in different biological responses in human pancreatic tumor cell lines.
Mill CP; Gettinger KL; Riese DJ
Exp Cell Res; 2011 Feb; 317(4):392-404. PubMed ID: 21110957
[TBL] [Abstract][Full Text] [Related]
2. Peptides for Dual Targeting of ErbB1 and ErbB2: Blocking EGFR Cell Signaling Transduction Pathways for Cancer Chemotherapy.
Patnaik SK; Swaroop AK; Nagarjuna P; Nanjan MJ; Chandrasekar MJN
Curr Mol Pharmacol; 2024; 17(1):e240223214012. PubMed ID: 36843255
[TBL] [Abstract][Full Text] [Related]
3. ErbB2 resembles an autoinhibited invertebrate epidermal growth factor receptor.
Alvarado D; Klein DE; Lemmon MA
Nature; 2009 Sep; 461(7261):287-91. PubMed ID: 19718021
[TBL] [Abstract][Full Text] [Related]
4. Neuregulin-1 and ALS19 (ERBB4): at the crossroads of amyotrophic lateral sclerosis and cancer.
Adashek JJ; Pandya C; Maragakis NJ; De P; Cohen PR; Kato S; Kurzrock R
BMC Med; 2024 Feb; 22(1):74. PubMed ID: 38369520
[TBL] [Abstract][Full Text] [Related]
5. A growing family: adding mutated Erbb4 as a novel cancer target.
Rudloff U; Samuels Y
Cell Cycle; 2010 Apr; 9(8):1487-503. PubMed ID: 20404484
[TBL] [Abstract][Full Text] [Related]
6. Development and application of high-throughput screens for the discovery of compounds that disrupt ErbB4 signaling: Candidate cancer therapeutics.
Cullum RL; Lucas LM; Senfeld JI; Piazza JT; Neel LT; Whig K; Zhai L; Harris MH; Rael CC; Taylor DC; Cook LJ; Kaufmann DP; Mill CP; Jacobi MA; Smith FT; Suto M; Bostwick R; Gupta RB; David AE; Riese Ii DJ
PLoS One; 2020; 15(12):e0243901. PubMed ID: 33378376
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological significance of concurrent ErbB receptor expression in human meningioma.
Torp SH; Arnli MB; Scheie D
Mol Clin Oncol; 2023 Oct; 19(4):79. PubMed ID: 37719042
[TBL] [Abstract][Full Text] [Related]
8. Profiling of ERBB receptors and downstream pathways reveals selectivity and hidden properties of ERBB4 antagonists.
Popović L; Wintgens JP; Wu Y; Brankatschk B; Menninger S; Degenhart C; Jensen N; Wichert SP; Klebl B; Rossner MJ; Wehr MC
iScience; 2024 Feb; 27(2):108839. PubMed ID: 38303712
[TBL] [Abstract][Full Text] [Related]
9. ERBB4 mutation analysis: emerging molecular target for melanoma treatment.
Lau C; Killian KJ; Samuels Y; Rudloff U
Methods Mol Biol; 2014; 1102():461-80. PubMed ID: 24258993
[TBL] [Abstract][Full Text] [Related]
10. The Yin and Yang of ERBB4: Tumor Suppressor and Oncoprotein.
Lucas LM; Dwivedi V; Senfeld JI; Cullum RL; Mill CP; Piazza JT; Bryant IN; Cook LJ; Miller ST; Lott JH; Kelley CM; Knerr EL; Markham JA; Kaufmann DP; Jacobi MA; Shen J; Riese DJ
Pharmacol Rev; 2022 Jan; 74(1):18-47. PubMed ID: 34987087
[TBL] [Abstract][Full Text] [Related]
11. A Review of HER4 (ErbB4) Kinase, Its Impact on Cancer, and Its Inhibitors.
El-Gamal MI; Mewafi NH; Abdelmotteleb NE; Emara MA; Tarazi H; Sbenati RM; Madkour MM; Zaraei SO; Shahin AI; Anbar HS
Molecules; 2021 Dec; 26(23):. PubMed ID: 34885957
[TBL] [Abstract][Full Text] [Related]
12. Unraveling ERBB network dynamics upon betacellulin signaling in pancreatic ductal adenocarcinoma in mice.
Hedegger K; Algül H; Lesina M; Blutke A; Schmid RM; Schneider MR; Dahlhoff M
Mol Oncol; 2020 Aug; 14(8):1653-1669. PubMed ID: 32335999
[TBL] [Abstract][Full Text] [Related]
13. The protective effect of betacellulin against acute pancreatitis is ERBB4 dependent.
Hedegger K; Stumpf F; Blum H; Graf A; Schmid RM; Lesina M; Algül H; Schneider MR; Dahlhoff M
J Gastroenterol; 2020 Mar; 55(3):317-329. PubMed ID: 31456099
[TBL] [Abstract][Full Text] [Related]
14. Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine.
Conway JR; Herrmann D; Evans TJ; Morton JP; Timpson P
Gut; 2019 Apr; 68(4):742-758. PubMed ID: 30396902
[TBL] [Abstract][Full Text] [Related]
15. Mig-6 deficiency cooperates with oncogenic Kras to promote mouse lung tumorigenesis.
Liu J; Cho SN; Wu SP; Jin N; Moghaddam SJ; Gilbert JL; Wistuba I; DeMayo FJ
Lung Cancer; 2017 Oct; 112():47-56. PubMed ID: 29191600
[TBL] [Abstract][Full Text] [Related]
16. ERBB4 Expression in Ovarian Serous Carcinoma Resistant to Platinum-Based Therapy.
Saglam O; Xiong Y; Marchion DC; Strosberg C; Wenham RM; Johnson JJ; Saeed-Vafa D; Cubitt C; Hakam A; Magliocco AM
Cancer Control; 2017 Jan; 24(1):89-95. PubMed ID: 28178720
[TBL] [Abstract][Full Text] [Related]
17. Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention.
Davis NM; Sokolosky M; Stadelman K; Abrams SL; Libra M; Candido S; Nicoletti F; Polesel J; Maestro R; D'Assoro A; Drobot L; Rakus D; Gizak A; Laidler P; Dulińska-Litewka J; Basecke J; Mijatovic S; Maksimovic-Ivanic D; Montalto G; Cervello M; Fitzgerald TL; Demidenko Z; Martelli AM; Cocco L; Steelman LS; McCubrey JA
Oncotarget; 2014 Jul; 5(13):4603-50. PubMed ID: 25051360
[TBL] [Abstract][Full Text] [Related]
18. Multiple Functional Motifs Are Required for the Tumor Suppressor Activity of a Constitutively-Active ErbB4 Mutant.
Gallo RM; Bryant IN; Mill CP; Kaverman S; Riese DJ
J Cancer Res Ther Oncol; 2013 Aug; 1(1):10. PubMed ID: 24791013
[TBL] [Abstract][Full Text] [Related]
19. Directing HER4 mRNA expression towards the CYT2 isoform by antisense oligonucleotide decreases growth of breast cancer cells in vitro and in vivo.
Nielsen TO; Sorensen S; Dagnæs-Hansen F; Kjems J; Sorensen BS
Br J Cancer; 2013 Jun; 108(11):2291-8. PubMed ID: 23695025
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
